Instruction 1(b).

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	IAIEMEN	IOFC	HAN	GES	IN BI	ENE	:FICIAI	OWNERS	HIP
obligations may continue. See									

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Noonberg Sarah B.					2. Issuer Name and Ticker or Trading Symbol Neoleukin Therapeutics, Inc. [ NLTX ]							Relationship of eck all applications X	cable) r	g Perso	10% Ow	ner		
(Last)	`	rst) ΓHERAPEUTIC	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 10/10/2019							Officer below)	r (give title )		Other (sp	pecify		
401 TERRY AVENUE NORTH					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	E W	A	98109									X Form filed by One Reporting Person  Form filed by More than One Reporting Person						
(City)	(Si	ate)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Date,			e, Transaction Disposed C Code (Instr. 5)		ities Acquired (A) o d Of (D) (Instr. 3, 4 a		Beneficia	s ally ollowing	Form:	Direct C Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	tion(s)			msu. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	erivative   Conversion   Date   Execution Date, ecurity   or Exercise   (Month/Day/Year)   if any		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares							
Stock Option (right to buy)	\$2.82	10/10/2019		A		22,000		(1)	10/09/2029	Common Stock	22,000	\$0.00	22,000	)	D			

## **Explanation of Responses:**

1. The options will vest as to 1/3 of the total number of shares underlying the options on each of October 10, 2020, October 10, 2021 and October 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

## Remarks:

/s/ Kamran Alam, Attorney-infact for Sarah B. Noonberg

10/15/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.